Literature DB >> 20502179

Adverse drug events in intensive care units: risk factors, impact, and the role of team care.

Sandra L Kane-Gill1, Judith Jacobi, Jeffrey M Rothschild.   

Abstract

Advances in diagnostic tests, technological interventions, and pharmacotherapy have resulted in spectacular results for many intensive care unit (ICU) patients who, in earlier generations, would have succumbed to their critical illness. At the same time, the complexity and intensity of care required for ICU patients is also associated with greater risks for harm resulting from care. As in other inpatient areas, medications are the most common type of therapy in ICUs and are also associated with the most frequent type of ICU adverse events. Critically ill patients are at high risk for adverse drug events for many reasons, including the complexity of their disease that creates challenges in drug dosing, their vulnerability to rapid changes in pharmacotherapy, the intensive care environment providing ample distractions and opportunity for error, the administration of complex drug regimens, the numerous high-alert medications that they receive, and the mode of drug administration. The clinical outcomes of adverse drug events can result in end-organ damage and even death. The costs of an adverse drug event can be substantial to healthcare systems with an additional $6,000-$9,000 for each event. The multiprofessional patient care team is one approach to promoting patient safety in the ICU.

Entities:  

Mesh:

Year:  2010        PMID: 20502179     DOI: 10.1097/CCM.0b013e3181dd8364

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  31 in total

Review 1.  Interventions to reduce medication errors in adult intensive care: a systematic review.

Authors:  Elizabeth Manias; Allison Williams; Danny Liew
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit and Prioritizing Future Research.

Authors:  Angela S Czaja; Pamela D Reiter; M Lynn Schultz; Robert J Valuck
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

3.  Zero tolerance prescribing: a strategy to reduce prescribing errors on the paediatric intensive care unit.

Authors:  Rachelle Booth; Emma Sturgess; Alison Taberner-Stokes; Mark Peters
Journal:  Intensive Care Med       Date:  2012-08-11       Impact factor: 17.440

4.  Developing a Business Plan for Critical Care Pharmacy Services.

Authors:  Brian L Erstad; Henry J Mann; Robert J Weber
Journal:  Hosp Pharm       Date:  2016-11

5.  Physician Perceptions of Consultant Pharmacist Services Associated with an Intervention for Adverse Drug Events in the Nursing Facility.

Authors:  Sandra L Kane-Gill; Joseph T Hanlon; Michael J Fine; Subashan Perera; Colleen M Culley; Stephanie A Studenski; Dave A Nace; Richard D Boyce; Nicholas G Castle; Steven M Handler
Journal:  Consult Pharm       Date:  2016-12-01

Review 6.  Impact of interventions designed to reduce medication administration errors in hospitals: a systematic review.

Authors:  Richard N Keers; Steven D Williams; Jonathan Cooke; Tanya Walsh; Darren M Ashcroft
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

7.  Voluntarily reported prescribing, monitoring and medication transfer errors in intensive care units in The Netherlands.

Authors:  B E Bosma; N G M Hunfeld; E Roobol-Meuwese; T Dijkstra; S M Coenradie; A Blenke; W Bult; P H G J Melief; M Perenboom-Van Dixhoorn; P M L A van den Bemt
Journal:  Int J Clin Pharm       Date:  2020-08-19

8.  Safety climate reduces medication and dislodgement errors in routine intensive care practice.

Authors:  Andreas Valentin; Michael Schiffinger; Johannes Steyrer; Clemens Huber; Guido Strunk
Journal:  Intensive Care Med       Date:  2012-12-07       Impact factor: 17.440

9.  Short acting insulin analogues in intensive care unit patients.

Authors:  Federico Bilotta; Carolina Guerra; Rafael Badenes; Simona Lolli; Giovanni Rosa
Journal:  World J Diabetes       Date:  2014-06-15

10.  Adverse drug events during AKI and its recovery.

Authors:  Zachary L Cox; Allison B McCoy; Michael E Matheny; Gautam Bhave; Neeraja B Peterson; Edward D Siew; Julia Lewis; Ioana Danciu; Aihua Bian; Ayumi Shintani; T Alp Ikizler; Erin B Neal; Josh F Peterson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.